Amgen (AMGN): FY26 Q2 earnings call, Aug 4, 2026

Tue, Aug 4Earnings callSpeaker-labelled transcriptAmgen

No Kalshi or Polymarket word markets were listed for Amgen’s Aug 4, 2026 earnings call (FY26 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

5 matches for “Oral”; 3 quoted, at least 25 words apart.

Speaker 12analystqa

…you for taking our questions. Just a two-part question on PCSK9. Merck's oral PCSK9 recently got approved. Also, can you comment on the contracted dynamics…

Murdo Gordoncompanyqa

…really easy regimen for patients to adhere to. We've seen limitations with orals, including with statins, where daily oral therapy does have some compliance and…

Murdo Gordoncompanyqa

I think this oral versus injectable is too simplistic a compare, and you really have to look at why do you take an LDL cholesterol…

Agents: this page as TSV at /api/v1/appearances/amgen:2026-08-04:earnings_call · words: /api/v1/brief?appearance=amgen:2026-08-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP